Related Experiment Videos
[Classification and treatment of DIC]
Insights
Disseminated intravascular coagulation (DIC) involves extreme blood clotting. Classifying DIC by coagulation or fibrinolysis dominance aids in selecting appropriate treatments for conditions like sepsis or acute promyelocytic leukemia.
Area of Science:
- Hematology
- Pathophysiology
- Medical Diagnostics
Context:
- Disseminated intravascular coagulation (DIC) is a complex syndrome with severe coagulation activation.
- Clinical outcomes, including bleeding and organ failure, depend on the underlying cause.
- The balance between coagulation and fibrinolysis activation is critical in DIC pathogenesis.
Purpose:
- To classify Disseminated intravascular coagulation (DIC) into distinct types based on coagulation and fibrinolysis patterns.
- To correlate specific DIC subtypes with underlying diseases and clinical manifestations.
- To emphasize the importance of DIC classification for guiding treatment strategies.
Summary:
- DIC is categorized into two main types: predominant coagulation activation (high thrombin-antithrombin III complex [TAT], elevated plasminogen activator inhibitor 1 [PAI]) often seen in sepsis with organ failure, and predominant fibrinolysis activation (high TAT and plasmin-alpha 2 plasmin inhibitor complex [PIC], normal PAI) common in acute promyelocytic leukemia (APL) with bleeding.
- Pre-DIC diagnosis involves monitoring decreasing platelets in sepsis and elevated Fibrinogen Degradation Products (FDP) and D-dimer in APL, leukemia, and cancer.
- Understanding these classifications is crucial for effective DIC management.
Impact:
- Provides a framework for differentiating DIC subtypes, aiding clinicians in tailoring treatment.
- Highlights the link between specific DIC patterns, underlying pathologies, and clinical presentation.
- Improves diagnostic approaches for early detection of pre-DIC states, potentially improving patient outcomes.
Abstract:
Disseminated intravascular coagulation (DIC) is characterized by extreme activation of intravascular coagulation, and clinical manifestations such as bleeding and/or multiple organ failure is sometimes observed in advanced cases of DIC. The balance of coagulation and fibrinolysis activation varies according to the underlying diseases of DIC. DIC cases are classified as the type with predominant coagulation activation and the type with predominant fibrinolysis activation in former type plasma levels of thrombin-antithrombin III complex (TAT) are greatly increased, and those of plasmin-alpha 2 plasmin inhibitor complex (PIC) are slightly increased. In addition plasma levels of plasminogen activator inhibitor 1 (PA1) are greatly increased, multiple organ failure is a major clinical manifestation in advanced cases and sepsis is a representative underlying disease. In the second type both plasma levels of TAT and PIC are greatly increased, plasma levels of PA1 are almost within normal limits. Bleeding is a major clinical manifestation in advanced cases and acute promyelocytic leukemia (APL) is a representative underlying disease. The classification of DIC should be considered when choosing treatment with DIC. Diagnosis of pre-DIC status is based on gradually decreasing platelets counts in sepsis and on mild elevation of FDP and D dimer in APL, leukemia and cancer.